Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers
Clinical Pharmacology in Drug Development · 2024-06 · 13 (6) · 611-620
DOI: 10.1002/cpdd.1373 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 22.02.2024. Verfasst von Ramachandra Sangana und 14 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Institutes for Biomedical Research, Cambridge, MA, USA. Hauptthemen laut MEDLINE: Omalizumab, Therapeutic Equivalency, Syringes, Healthy Volunteers. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Omalizumab is an anti‐IgE monoclonal antibody currently approved for the treatment of asthma, nasal polyps/chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria. Omalizumab is available as an injection in a prefilled syringe (PFS) with a needle safety device (NSD). New product configurations were developed to reduce the number of injections per dose administration, improve patient convenience and treatment compliance. The objective of this randomized open‐label 12‐week study was to demonstrate pharmacokinetic bioequivalence between (1) new PFS with autoinjector (PFS‐AI), (2) new PFS‐NSD configuration, and (3) current PFS‐NSD configuration. Each new configuration was considered bioequivalent to the current configuration if the confidence intervals (CIs) for the geometric mean ratios (GMR) were contained in the 0.80‐1.25 range for maximum concentration (C max ), area under the concentration‐time curve until the last quantifiable measurement (AUC last ), and AUC extrapolated to infinity (AUC inf ). Safety was assessed throughout the study. In total, 193 healthy volunteers were randomized at 1:1:1 ratio to omalizumab 1×300 mg/2 mL via new PFS‐AI (n = 66), omalizumab 1×300 mg/2 mL via new PFS‐NSD (n = 64), or omalizumab 2×150 mg/1 mL via current PFS‐NSD (n = 63). Comparing new PFS‐AI versus current PFS‐NSD, the GMRs were: C max , 1.085; AUC last , 1.093; AUC inf , 1.100. Comparing new PFS‐NSD versus current PFS‐NSD, the GMRs were: C max , 1.006; AUC last , 1.016; AUC inf , 1.027. The 95% CIs for all GMR parameters were contained within the 0.80‐1.25 range. Safety findings were consistent with the known safety profile of omalizumab. Single‐dose omalizumab administered as the new PFS‐AI or new PFS‐NSD was bioequivalent to the current PFS‐NSD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
- Genentech Research and Early Development, South San Francisco, CA, USA.
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
- Novartis Pharma AG, Basel, Switzerland.
- Novartis Healthcare Pvt, Hyderabad, India.
Zitieren
APA
Sangana, R., Xu, Y., Shah, B., Tian, X., Zack, J., Shakeri-Nejad, K., Kalluri, S., Jones, I., Ligueros-Saylan, M., Taylor, A. F., Jain, D. K., Scosyrev, E., Uddin, A., Laurent, N., & Paganoni, P. (2024). Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers. Clinical Pharmacology in Drug Development, 13(6), 611-620. https://doi.org/10.1002/cpdd.1373
Vancouver
Sangana R, Xu Y, Shah B, Tian X, Zack J, Shakeri-Nejad K, et al. Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers. Clinical Pharmacology in Drug Development. 2024;13(6):611-620. doi:10.1002/cpdd.1373
BibTeX
@article{Sangana2024,
author = {Sangana, Ramachandra and Xu, Yan and Shah, Bharti and Tian, Xianbin and Zack, Julia and Shakeri-Nejad, Kasra and Kalluri, Sampath and Jones, Ieuan and Ligueros-Saylan, Monica and Taylor, Angel Fowler and Jain, Devendra Kumar and Scosyrev, Emil and Uddin, Alkaz and Laurent, Nathalie and Paganoni, Paola},
title = {Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
volume = {13},
number = {6},
pages = {611--620},
doi = {10.1002/cpdd.1373}
}
EUVIMED